FINWIRES · TerminalLIVE
FINWIRES

Alphamab Oncology Swings to Loss in 2025

発信

-- Alphamab Oncology (HKG:9966) logged 113.9 million yuan in attributable loss for 2025, swinging from a profit of 166.3 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.

The cancer therapy developer's shares fell by more than 3% in late-morning trade on Wednesday.

Loss per share was 0.12 yuan, compared with earnings of 0.17 yuan in the prior year.

Revenue fell to 566.2 million yuan from 640.1 million yuan in 2024, figures showed.

関連記事